Trial · NCT03374254
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) | Cohort A Part 1: Pembrolizumab +Binimetinib 30 mg | 16.7 | 80% Confidence Interval 4.0 to 39.1 | Percetange of Participants | |
| Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) | Cohort A Part 1: Pembrolizumab +Binimetinib 45 mg | 0.0 | 80% Confidence Interval 0.0 to 10.2 | Percetange of Participants | |
| Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) | Cohort B Part 1: Pembrolizumab + mFOLFOX7 | 0.0 | 80% Confidence Interval 0.0 to 9.6 | Percetange of Participants | |
| Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) | Cohort C Part 1: Pembrolizumab + mFOLFOX7 + Binimetinib 30 mg | 27.3 | 80% Confidence Interval 13.4 to 45.0 | Percetange of Participants | |
| Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) | Cohort D Part 1: Pembrolizumab + FOLFIRI | 7.1 | 80% Confidence Interval 1.4 to 19.4 | Percetange of Participants | |
| Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) | Cohort E Part 1: Pembrolizumab + FOLFIRI + Binimetinib 30 mg | 33.3 | 80% Confidence Interval 17.0 to 53.1 | Percetange of Participants | |
| Percentage of Participants Who Experienced Dose-Limiting Toxicity (DLT) | Cohort E Part 1: MK-3475 200 mg Q3W + FOLFIRI Q2W + Binimetinib 45 mg BID | 45.5 | 80% Confidence Interval 28.4 to 63.3 | Percetange of Participants | |
| Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | Cohort A | 0.0 | 95% Confidence Interval 0.0 to 16.8 | Percentage of participants | |
| Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | Cohort B | 61.3 | 95% Confidence Interval 42.2 to 78.2 | Percentage of participants | |
| Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | Cohort C | 27.3 | 95% Confidence Interval 6.0 to 61.0 | Percentage of participants | |
| Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | Cohort D | 25.0 | 95% Confidence Interval 11.5 to 43.4 | Percentage of participants | |
| Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | Cohort E | 20.0 | 95% Confidence Interval 5.7 to 43.7 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03374254/results